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This article reviews the association between bone and artery disease, with particular relevance to progenitor cells. The
review was based on insight gained by analysis of previous publications and on-going work by the authors. A large
number of studies have demonstrated a correlation between bone pathology, particularly osteoporosis, and atheroscle-
rosis. In this review we highlight the particular aspect of bone marrow progenitor cells in the bone-artery link. Progenitor
cells, primarily those believed to give rise to endothelial cells, have been inversely correlated with atherosclerosis severity
and risk factors. Therapeutic approaches aimed at manipulating progenitor cells in revascularization and vascular repair
have demonstrated some promising results. Subtypes of progenitor cells have also been linked with vascular pathology,
however, and further studies are required to assess relative beneficial and pathologic effects of bone marrow–derived
progenitors. Further understanding of the link between bone and artery pathophysiology is likely to be of significant
value in developing new therapies for vascular disease. ( J Vasc Surg 2007;46:590-600.)Bone marrow–derived monocyte-macrophages have
been demonstrated to be central in the pathogenesis of a
number of arterial diseases, including atherosclerosis and
intimal hyperplasia. Interest in the link between bone and
artery disease, however, has become much more marked
with the demonstration that bone marrow stem cells can
give rise to endothelial and vascular smooth muscle cells
(VSMCs). The presence of cells and matrix within the
artery wall in vascular disease, which are often associated
with bone remodelling, suggests an intimate, yet complex
interaction between these two tissues. In this review we
discuss the present evidence linking bone and artery and in
particular highlight the importance of bone marrow de-
rived progenitor cells.
ASSOCIATION BETWEEN BONE PATHOLOGY
AND ARTERIAL DISEASE
Cardiovascular disease has been associated with a num-
ber of bone pathologies, including Paget disease, osteopo-
rosis, and renal osteodystrophy.1-3 The most consistent
association has been demonstrated between osteoporosis
and atherosclerosis, particularly arterial mineralization.3-10
A number of studies have demonstrated an association
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590between the severity of bone mineral density loss and
vascular calcification or other measures of atherosclero-
sis.4,9 Low bone mineral density has been associated with
previous myocardial infarction (MI), carotid atherosclero-
sis, arterial stiffness, and subsequent cardiovascular
events.5,7,8,10 Jorgensen et al6 found in a prospective study
of 2733 women that subjects with echogenic carotid
plaques were more at risk of subsequent fractures during a
6-year follow-up. Bagger et al4 similarly demonstrated an
independent association between aortic calcification and
subsequent bone loss and fracture risk.4 The incidence of
femur fractures has been correlated with coronary calcifica-
tion.3
Mechanisms underlying the association between bone
and artery pathology (Fig 1) may include:
(a) Common risk factors: Age, genetic associations, dyslip-
idemia, oxidative stress, inflammation, hyperhomo-
cystinemia, hypertension, diabetes, and smoking have
been associated with bone mineral density loss in
some but not all studies.11-14 These factors are
well-recognized risk factors for atherosclerosis.
(b) Related but contrasting biology: Significant advances in
the understanding of bone biology have identified a
number of processes in bone turnover related to ath-
erosclerosis. Examples of proteins important in regu-
lating bone homeostasis and remodelling that have
been implicated in atherosclerosis include matrix Gla
protein, osteoprotegerin, receptor activator of necrosis
factor-B ligand, osteopontin, and bone morphogenic
proteins, among many others.15,16 Possibly as a result
of the different environments of bone and artery, these
molecules appear to play different roles in the two sites.
For example, osteoprotegerin protects bone against
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In addition, oxidative stress factors such as oxidized
lipoproteins have been shown to modulate vascular and
bone cells differently. Oxidative stress enhances osteo-
blastic differentiation of calcifying vascular cells but
inhibits that of bone cell. These opposing effects may
contribute to the association of bone destruction with
arterial mineralization.17
(c) Association of cellular elements: The association of
bone-related factors with atherosclerosis and the pres-
ence of mineralized bone deposits within atheroscle-
rotic plaques suggests the potential of cells present
within the artery wall to promote osteogenesis.18 Cells
important in bone turnover, including osteoblasts and
osteoclast-like cells, have counterparts in the artery
wall.18 In addition, a number of different cells types
found within the artery wall, including VSMCs, have
osteogenic potential under experimental conditions in
vitro.19 Whether these bone-remodelling cells have
differentiated from existing cells in the artery wall,
under the influence of injury-induced local changes and
factors, or are the progeny of bone marrow stem cells
seeding sites of vascular injury is unclear. However, the
finding that bone marrow–derived cells are involved in
both vascular repair and pathology suggests a complex
relationship between these bone marrow progenitor
cells and the artery wall.20 These cellular links are the
focus of this review.
(d) Passive mineral based link:The systemic release of bone
Fig 1. Bone and artery pathologies share common risk
(a) common risk factors including age, genetic associat
smoking; (b) common signalling pathways including th
receptor activator of nuclear factor B (RANK)/osteop
remodelling and arterial pathology; and (c) similar ce
remodelling and reported in calcified vascular lesions. T
process of some bone pathologies, including osteoporos
Occlusion of blood vessels mediated by (e) atherosclero
mineral density.products such as calcium could lead to their passivedeposition in arteries. The focal nature of the mineral-
ization, the incorporation of elements of bone, includ-
ing lamellar bone, and the associated matrix proteins
make this mechanism unlikely to be of primary impor-
tance, despite some evidence from animal models.18,21
(e) Effects of atherosclerosis on bone blood supply: Loss of
bone mineral density due to atherosclerotic occlusion
of bone blood supply has been suggested as a further
link between vascular and bone disease.4
PROGENITOR CELLS
Identification of progenitor cells in humans.
Progenitor cells are naive cells capable of infinite renewal
before differentiation into more mature populations. A
number of different cell populations isolated from bone
marrow and peripheral blood of humans and animal models
have been demonstrated to differentiate into endothelial
cells, VSMCs, blood cells, and osteocytes in vitro.22 This
has led to the concept of circulating progenitor cells for
endothelium (EPCs), VSMCs (SPCs), and bone or ectopic
calcification. These cell types remain controversial, and
there is debate about how they should be identified, what
roles they play in physiology and disease, and whether they
can be manipulated for therapeutic purposes.20,23 Identifi-
cation of progenitor cells is confounded by their remark-
able lineage plasticity; that is, they can differentiate into a
variety of progeny once stimulated appropriately. Com-
monly used methods of identification of progenitor cells
include flow cytometry, cell culture, or a combination of
rs and mechanisms. Bone and arterial pathologies share
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heart, and adventitia have also been shown to differentiate
into endothelial and VSMCs in vitro.29,30 In the embryo,
VSMCs can arise as a result of transdifferentiation of endo-
thelium or directly from mesoderm or neuroectodermal
(aortic arch).31,32 In the adult, it is also likely that vascular
cells (endothelial cells and VSMCs) arise from a variety of
sources, as emphasized by the ability of both donor and
recipient cells to generate outgrowth endothelial cells in
peripheral blood mononuclear cells from human bone mar-
row transplant patients.33
At present, the most convincing data support the exis-
tence of EPCs: large numbers of review articles and high-
impact publications have appeared since their original dis-
covery in 1997.20,28,34 Even for this cell type, however,
there is controversy about identification.35 For example,
circulating endothelial cells (which may be sloughed off an
inflamed endothelium during apoptosis or necrosis) or
microparticles of these have been identified by some inves-
tigators and their presence interpreted as a measure of
arterial disease severity.24
Control of progenitor cells. The maintenance and
mobilization of stem cells in the bone marrow is deter-
mined by the local microenvironment, the “stem cell
niche,” which consists of bone marrow stromal cells such as
osteoblasts, endothelial cells, and fibroblasts.36 Their re-
lease from this niche and mobilization into the circulation
requires a complex sequence of events and cell types. Ad-
hesive interactions between stem cells and stromal cells are
Table I. Human progenitor cells
rogenitor
Frequency in peripheral
blood
Surface marker
present
HSC25 1/10-100,000 blood cells CD34*
MSC25 Less than HSC CD105, CD73
EPC20 Less than HSC CD34, CD133,
VEGFR-2*
CEC24 1-10 cells/mL CD146, Ulex
europaeus lectin
SPC27 Unknown SMA, myosin hea
chain, calponin,
CD34, Flk-
1,VEGFR-2, 5
OPC26 1%-2% of PBMNCs OC, BAP
HSC, Hematopoietic stem cell; MSC, mesenchymal stem cell; EPC, endo
circulating endothelial cell; BM, bone marrow; CSFs, colony stimulating
humans, flk-1 in mice; SMA, smooth muscle cell–specific  actin; MM
PBMNCs, peripheral blood mononuclear cells; OC, osteocalcin; BAP, bone
*CD34– HSC/EPCs also described, CD34– EPC suggested to have more
mature leukocyte markers such as CD45 and CD14.responsible for stem cell homing to the bone marrow andinclude vascular cell adhesion molecule-1 and the CXC
chemokine receptor 4/stromal cell–derived factor-1 che-
motactic axis.
Mobilizing factors reverse the homing process by in-
creasing the motility of the stem cells and facilitating their
release from the stromal cells, which enables stem cells to
leave the bone marrow by transendothelial migration.37
Difficulties in precisely discriminating the various progeni-
tor cell types within the mononuclear fraction of bone
marrow and peripheral blood, such as EPC, SPCs, hemo-
poietic stem cells (HSCs), and their multipotent ancestors,
has hindered definitive descriptions of the specific mecha-
nisms that each use to exit the bone marrow. Peripheral
blood EPCs and SPCs differ in their expression of surface
integrins and attachment to extracellular matrix proteins.
Whether these differences also occur within the bone mar-
row and their release is modulated differently is un-
known.38 Arrival of progenitor cells to the sites of vascular
disease can be considered to involve their mobilization
from the bone marrow or other resident sites, recruitment
to the artery, and differentiation within the vessel. Control
of these different processes will be discussed in the follow-
ing paragraphs (Fig 2).
Mobilization. Mature immune cells, including my-
eloid and lymphoid cells, are continually released from the
bone marrow into the circulation during normal homeosta-
sis, whereas very low numbers of primitive progenitor cells
enter the circulation under these conditions. Vascular in-
jury, tissue ischemia, exercise, and tumor growth have all
Surface markers
absent Behavior in culture
Lineage Nonadherent, can differentiate into
multiple lineages: red blood
cells, monocytes, leukocytes
CD45 Adherent, can differentiate into
multiple cell types: osteocytes,
chondrocytes, adipocytes
Differentiate into endothelial cells,
form tubes on matrigel, highly
proliferative, can be genetically
modified
CD34, CD133 Maybe apoptotic or necrotic
Tie-2 receptor, CD31 Hill & valley appearance after 2
weeks PDGFBB
Form mineralization nodules in
vitro & in vivo
progenitor cell; SPC, vascular smooth muscle cell progenitor cell; CEC,
; VEGF(R2), vascular endothelial growth factor (receptor-2) or KDR in
atrix metalloproteinase-9; PDGF-BB, platelet-derived growth factor-BB;
fic alkaline phosphatase; OPC, osteogenic progenitor cell.
othelialization potential by some investigators.20 Lineage markers includes
1
vy
1
thelial
factors
P-9, m
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bone marrow is mainly mediated by factors increasing
the activity of proteinases, such as elastase, cathepsin G, and
the matrix metalloproteinases (Table I). For example, gran-
ulocyte colony-stimulating factor (GCSF) releases elastase
and cathepsin from neutrophils, which cleave a number
of proteins that keep progenitor cells resident within the
bone marrow, including vascular cell adhesion molecule-1,
stromal cell–derived factor-1, and CXC chemokine recep-
tor 4.39,40 This results in loss of the adhesive bond between
bone marrow stromal cells and progenitor cells, thereby
liberating these cells from their stem cell niche. In addition,
stromal cell–derived factor-1 and vascular endothelial
growth factor (VEGF) induce matrix metalloproteinase-9,
which cleaves the membrane-bound kit ligand resulting in
the release of soluble kit ligand. Soluble kit ligand confers
signals to enhance the mobility of progenitor cells, promot-
ing their movement into the circulation.41
Recruitment. After mobilization, circulating vascular
progenitor cells home to sites of injured ischemic tissue or
growing malignant tumors, accelerating the tissue repair
and revascularization process.42 This multistep process of
chemoattraction, adhesion, transmigration, and differenti-
ation has not yet been fully elucidated, although it likely
shares many characteristics with leukocyte infiltration. Im-
portant factors in the chemoattraction of EPCs include
VEGF and stromal cell–derived factor-1. VEGF is upregu-
lated after MI and attracts the VEGF receptor-positive
EPCs to the site of ischemia.43
Similarly, endothelial cells respond to damage by
Table I. Continued
Origin M
BM CSFs, SDF-1
BM, possibly other tissues Unclear
BM putative hemangioblast, possible common
HSC & EPC28
Tissue ischem
SDF-1, VE
Damaged endothelium Atherosclero
BM Unknown
BM Unknownrelease of stromal cell–derived factor-1, a process con-trolled by hypoxia-inducible factor-1, which thus creates
a chemotactic gradient for CXC chemokine receptor
4–positive vascular progenitor cells to injured and isch-
emic tissue.44 Molecules believed to be important in the
adhesion of progenitor cells to the target tissue include
selectins, integrins, CD31, and monocyte chemotactic
protein-1.22
The control of recruitment of SPCs from the bone
marrow is less clear and controversial, particularly as the
precise origin of VSMCs has not been clarified. Some
authors have suggested that VSMCs in the neointima of
vascular graft lesions are derived from tissue-resident pro-
genitor cells, whereas others have demonstrated a signifi-
cant proportion of VSMCs in plaques were derived from
donor bone marrow in transplant experiments, suggesting
the recruitment of bone marrow–derived SPCs.45-47
Differentiation. VEGF has been implicated in endo-
thelial differentiation.28 The genetic pathways underlying
progenitor cell differentiation are being explored in mice
models. For example, the protein kinase Pim-1 and the
transcription factor Hex are required for EPC differentia-
tion,48,49 whereas transforming growth factors 1 and 3
and platelet-derived growth factor BB are implicated in
SPC differentiation.22 Debate continues about whether
transdifferentiation occurs.50 Similarly, there is controversy
about whether cells can de-differentiate from a committed
but not terminally differentiated lineage to a more primitive
multipotent progenitor in the adult vessel wall and are
capable of significant changes in their phenotypes in re-
ation Destinations, roles
Many roles: oxygen carriage, inflammation
Repair versus disease, immunosuppression,
HSC engrafting & hematopoiesis
MP-9, G-CSF, Endothelial repair, vasculogenesis
flammation Marker of disease state
Unknown: possibly atherosclerosis, intimal
hyperplasia, vascular repair
Unknownobiliz
ia, M
GF
sis, insponse to alterations in their local environment.51
mine
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Endothelium progenitor cells and artery disease
Animal data. A study of bone marrow transplantation
in an animal model of mice expressing green fluorescent
protein reported that donor cells give rise to new endothe-
lium after vascular injury.52 Factors associated with EPC
mobilization, including GCSF and statins, have been re-
lated to increased speed of re-endothelialization and re-
duced intimal hyperplasia.53,54 Bone marrow from younger
nonatherosclerotic mice has been demonstrated to reduce
atheroma development in older mice.55,56 These studies
support the ability of bone marrow–derived EPC to effect
vascular repair, thereby reducing the development of inti-
mal hyperplasia and atheroma.
Human data. Data from a large number of studies in
human subjects suggests that EPC numbers are reduced in
atherosclerosis in relation to its severity and risk factors.57-63
For example, bone marrow–derived mononuclear cells have
reduced ability to form EPC colony–forming units and
migration when removed from patients with heart failure
compared with healthy controls.59 EPC number has been
inversely correlated with carotid intima-media thickness,
severity of coronary artery disease, lower limb ischemia,
transplant atherosclerosis, and cerebrovascular disease, and
positively associated with endothelial dependent relax-
ation.57,60,62,64-66 Composite cardiovascular risk factor
Fig 2. Circulating progenitor cells (PC) as a link betwe
bone marrow stem cell niche via their interactions w
fibroblasts. CXC chemokine receptor 4 (CXCR4)/stro
important receptor/ ligand pairs that maintain progenit
vascular injury, inflammation, tissue ischemia, or mobil
result in the production of proteinases from various ce
Progenitor cells leave the stem cell niche via transend
Vascular endothelial cells release chemoattractant molecu
SDF-1 in response to endothelial damage, which recruit
circulation. (iii) Recruited progenitor cells may traverse
underlying intima. Here, under the influence of unknow
endothelial cells, VSMCs, or osteogenic cells capable ofscores and individual predictors of atherosclerosis havebeen extensively associated with reduced number and func-
tion of EPC; for example, hypertension, homocysteine,
C-reactive protein, renal failure, hypercholesterolemia, an-
giotensin II, diabetes, and smoking.58,62,67-71
Although factors demonstrated to be protective against
atherosclerosis have been correlated with increased num-
bers of EPCs, such as high-density lipoprotein, estrogen,
statins, and angiotensin II inhibitors,54,69,72,73 also of im-
portance is that EPC numbers have been shown to predict
subsequent cardiovascular events. Schmidt-Lucke et al,61
in a study of 120 individuals followed up for a median of 10
months, demonstrated the number of EPCs to be indepen-
dently negatively correlated with the risk of cardiovascular
events.61 In a study of 519 patients with coronary artery
disease, Werner et al74 demonstrated that cardiovascular
events were associated with EPC tertiles. After adjustment
for other risk factors, increased EPC number was associated
with lower cardiovascular death at a hazard ratio of 0.31
(95% confidence interval, 0.16 to 0.63).74
Thus, it has been suggested that impaired EPC repair
of recurrent endothelial injury is instrumental in athero-
sclerosis development and progression.20 In contrast to the
summarized findings just presented, a recent study reported
that the number of circulating EPCs was greater in patients
with abdominal aortic aneurysm compared with age-matched
controls.75 Whether the role of EPCs in occlusive atheroscle-
rosis and aortic aneurysm is different is presently unclear.
e bone and artery. Progenitor cells are maintained in the
romal cells such as osteoblasts, endothelial cells, and
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Smooth muscle progenitor cells and artery disease
Animal models. A number of potential sources of
SPCs have been suggested, including bone marrow (HSC
and mesenchymal stem cells [MSCs]), adventitia, skeletal,
and cardiac muscle.76 To track the destination of SPCs,
most investigators have used a protocol involving the injec-
tion of labelled donor bone marrow into lethally irradiated
animals, particularly mice. The presence of labelled donor
cells within arterial disease sites is then inferred as being
identical to the total contribution made by the bone mar-
row in a nonirradiated animal. Irradiation may not eradi-
cate all recipient bone marrow, however, meaning that
these studies could underestimate the bone marrow contri-
bution to artery disease. For example, a number of studies
have suggested that stromal cells, which could give risk to
MSCs, remain after irradiation.77
A few studies have investigated the effect of injecting
mononuclear cells in the absence of irradiation (Table
II).56,78,79 A number of studies have supported the role of
bone marrow–derived SPCs in arterial pathologies, includ-
ing transplant atherosclerosis, intimal hyperplasia, and ath-
erosclerosis associated with hyperlipidaemia.45,47,80-83 A
recent study using high-resolution microscopy has ques-
tioned the findings from these earlier investigations. Bent-
zon et al84 studied atheroma in apolipoprotein E deficient
(ApoE–/–) mice that had their bone marrow reconsti-
tuted from sex-mismatched ApoE–/– green fluorescent
protein–positive animals. Using confocal microscopy,
the investigators reported that no green fluorescent pro-
tein or Y chromosome–positive VSMCs were present in
approximately 10,000 -actin positive cells examined.
Sites assessed included spontaneous plaques and intimal
hyperplasia induced by placement of transplanted segments
of arteries in the presence of an external cuff. A number of
other studies have also failed to find significant bone mar-
row contribution to artery disease, although it is difficult to
know how the findings in these different models relate to
human atherosclerosis.85,86
Human data. VSMCs have been grown from human
peripheral blood mononuclear cells.27 Caplice et al,87 using
fluorescence in situ hybridization to identify X and Y chro-
mosomes in atheroma excised from patients who had pre-
viously received sex-mismatched bone marrow transplants,
reported that 10% of VSMCs within atherosclerotic arteries
were of donor origin.87 Further studies are required to
resolve the importance of SPCs in human atherosclerosis
and intimal hyperplasia.
Osteoblastic progenitor cells and artery disease
More recently, progenitor cells positive for osteocalcin
and bone-specific alkaline phosphatase have been identified
as osteoblastic progenitor cells (OPCs) in the peripheral
blood. These cells not only express bone-related proteins
but are also capable of adherence, replication, and forma-
tion of mineralized nodules in vitro as well as forming bonein an in vivo mice transplantation assay.26 The origin of
these cells is believed to be in the nonadherent bone
marrow population, which contains a pool of cells with
osteogenic potential as well as cells with both hematopoi-
etic and mesenchymal (eg, osteoblastic) reconstituting abil-
ity.88 OPCs represent 1% to 2% of the mononuclear cells in
peripheral circulation, and their number increases during
times of increased bone formation such as pubertal growth
or after bone fracture.26
In addition to contributing to physiologic bone forma-
tion, the presence of osteoblastic cells in peripheral blood
suggests their possible role in the pathogenesis of ectopic
ossification. Vascular calcification, for example, seems to be
an active, cell-mediated process involving osteoblast-like
cells. Because the naive vasculature contains no osteoblasts,
it has been suggested that deregulated mobilization, hom-
ing, and proliferation of circulating OPCs may play a role in
the calcification of blood vessels and heart valves as a
common complication of atherosclerosis.89 Further studies
are required to support or refute these theories, particularly
as there is increasing interest in injecting fractions of bone
marrow, which could thus be associated with vascular cal-
cification.90
Other progenitor cells and artery disease
In addition to progenitor cells, HSC and MSC have
been suggested to play a role in vascular physiology and
pathology (Table I). HSC are multipotent stem cells that
give rise to all cells of the blood lineage, whereas MSC are
capable of differentiating into various other cell types,
including osteocytes, chondrocytes, fibroblasts, myocytes,
and adipocytes. In recent years, it has been proposed that
these cells can circulate to the site of injury, where they
contribute to myocardial repair and regeneration. Numer-
ous groups have reproduced the observation of stem cell–
induced angiogenesis, but the possibility of myogenesis has
also been suggested.91 In culture conditions and animal
models, the differentiation of MSC to cardiomyocyte-like
cells is well documented, but extrapolation to clinical set-
tings faces a variety of obstacles and uncertainties. When
injected into infarct tissue, MSCs may enhance regional
wall motion and prevent remodelling of the remote, non-
infarcted myocardium.92 The secretion of angiogenic cyto-
kines by MSC may play an important role in their angio-
genic properties.93 Organ-resident stem cells have also
been identified such as cardiac or adventitial, but their role
in physiology and pathology requires further investigation.
THERAPEUTIC MANIPULATION OF
PROGENITOR CELLS
Given our present knowledge of the function and
mechanisms controlling movement of progenitor cells, a
number of therapeutic benefits of manipulating them have
been suggested and investigated. Although most of the
research has been aimed at EPCs, most studies have in-
volved relatively crude isolates of cells. In theory, it would
be possible to influence progenitor cells by altering mobi-
lization, recruitment, and differentiation. Studies to date
r 5 da
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Revascularization
Animal studies. A number of investigators have stud-
ied the effect of isolation of fractions of mononuclear cell
populations using surface markers (eg, Flk-1), expansion
ex vivo under preferential growth conditions with or with-
out genetic manipulation, and injection. For example,
Kawamoto et al94 demonstrated that human peripheral
blood mononuclear cells, expanded ex vivo when injected 4
weeks after MI induction in a rat model, improved the
histologic appearance and function of the heart. Similarly,
CD34-positive (not CD34-negative) GCSF–mobilized hu-
man peripheral blood mononuclear cells injected intrave-
nously in rats with ischemic myocardium led to new vessel
formation plus improved myocardial function.95 Kalka
et al96 reported that injecting human peripheral blood
mononuclear cells into athymic mice in which the femoral
artery had been excised led to limb salvage in 59% com-
pared with 8% in controls.
Similar findings have been reported in athymic rats and
mice receiving stromal cell derived factor-1 injections.97,98
The mechanisms underlying these benefits are likely a com-
bination of a low rate of incorporation of EPCs leading to
local vasculogenesis, and release of cytokines and chemo-
kines promoting angiogenesis.86,99 The incorporation of
EPC in mice is reported to be only around 1% of injected
cells in basal conditions but can increase to 10% during
endothelial injury.100
Human studies. A number of trials have investi-
gated the effect of intracoronary and peripheral injection
of mononuclear cells in the treatment of MI, heart
failure, and lower limb ischemia.101,102 In the biggest
study 204 patients were randomized after acute MI
between intracoronary injection of bone marrow-derived
mononuclear cells or placebo medium.103 The authors
reported a reduction in the combined end point of death,
recurrence of MI, or revascularization from 40% to 23%
at 1 year (P  .01).
Some but not all authors have reported small but
significant improvement in myocardial function, particu-
Table II. Studies examining the effect of bone marrow in
Study Donor species Donor age Cel
78 ApoE–/–- 10 wks BM
78 ApoE–/– 10 wks Splenic
56 ApoE–/–- 4 wks (6 mon) BMU/A
79 C57BL/6 (GFP) NS BM-MN
79 ApoE–/– NS BM-MN
NS, Not stated; MNCs, mononuclear cells; BM, bone marrow cells unspeci
adherent BM cells (stromal/ mesenchymal); ApoE–/–, apolipoprotein E defi
*Atherosclerosis was measured by microscopic area at the aortic sinus in all
†P  .01 compared with control group.
‡Cultured in endothelial media to convert to endothelial progenitor cells folarly in response to bone marrow–derived rather than pe-ripheral blood mononuclear cells.101 Homing studies sug-
gest that only 1% to 3% of infused cells are retained in the
heart, suggesting that the mechanisms underlying any ben-
efit may not relate to myocyte regeneration.104
A number of small studies have assessed the value
of peripheral injection of mononuclear cells harvested from
the bone marrow or peripheral blood.105-109 These studies
have reported improvement in walking ability, healing
of ulcers, peripheral tissue oxygen levels, endothelial-
dependent relaxation, and angiographic appearance in pa-
tients receiving autologous mononuclear cells.106-109 A
small randomized trial in patients with non-reconstructable
peripheral artery disease suggested that bone marrow–
derived mononuclear cell injection or GCSF improved limb
salvage.105
Vascular repair
Because EPCs have been implicated in the normal
physiology of vascular repair, mechanisms to promote them
would be expected to reduce arterial disease. In a rabbit
carotid balloon injury model, EPC transplant led to im-
proved re-endothelialization and reduced intimal hyperpla-
sia, particularly when endothelial nitric oxide synthase over-
expression was induced.110,111 GCSF administration
before angioplasty in rats led to re-endothelialization and
reduced intimal hyperplasia.53 Therapy aimed at improving
survival of EPCs, such as with statins, glitazones, and
estrogen, are associated with reduced artery disease in
animal models and patients.112-114
Bioengineering of grafts and stents
EPC seeding and their mobilization has been reported
to improve endothelialization of polytetrafluoroethylene
grafts and stents in animal models.110,115 Sin’oka et al116
have reported the use of polymer tubes seeded with autol-
ogous bone marrow in children requiring pulmonary artery
or vein replacement. They report excellent graft patency
and that the diameter of grafts increases over time in
keeping with recipient growth. Further studies are required
to assess whether this approach might improve the patency
n without irradiation in mice models of atherosclerosis
No. Recipient species Recipient age
106 ApoE–/– 10 wks
s‡ 106 ApoE–/– 10 wks
ched 2  106 ApoE–/– 3 wks
106 ApoE–/–& ischemia 14 wks
106 ApoE–/–& ischemia 14 wks
MU, nonplastic adherent BM cells (hematopoietic enriched); BMA, plastic
mice; GFP, green fluorescent protein.
s.
ys.jectio
l type
MNC
enri
Cs
Cs
fied; B
cient
studieof prosthetic grafts or stents.
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A large number of studies support an association be-
tween bone and artery disease. The mechanisms underlying
this association are starting to be understood and appear to
include the involvement of bone marrow–derived cells in
the normal repair and pathology of arteries. Further under-
standing of these mechanisms will be fundamental in at-
tempts to utilize progenitor cells in therapy.
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